Skip to main content Skip to section navigation Skip to footer
Immunovant, Inc.
  • Home
  • About Us
  • Pipeline
    • Mechanism of Action
    • Indications
  • For Investors
    • Overview
    • Immunovant R&D Day
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Analyst Coverage
    • Governance
  • Join Us
    • Our Benefits
    • Our Careers
  • Contact Us

Press Releases

For Investors

For Investors

  • Overview
  • Immunovant R&D Day
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Analyst Coverage
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Nov 07, 2022 8:00am EST

Immunovant to Present at Guggenheim 4th Annual Immunology and Neurology Day on November 14th

Nov 04, 2022 7:00am EDT

Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended September 30, 2022

Oct 04, 2022 8:45am EDT

Immunovant Announces Pricing of $75.0 Million Underwritten Offering of Common Stock

Sep 28, 2022 10:45am EDT

Immunovant Announces IMVT-1402, a Next Generation Anti-FcRn

Sep 21, 2022 8:00am EDT

Immunovant to Present at Roivant Investor Day on September 28th

Sep 09, 2022 8:00am EDT

Immunovant to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14th

Sep 07, 2022 7:11am EDT

Immunovant Announces Two New Development Programs for Batoclimab

Aug 24, 2022 8:00am EDT

Immunovant to Host Investor Webcast to Announce Two New Indications for Batoclimab on September 7, 2022

Aug 05, 2022 7:00am EDT

Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended June 30, 2022

Jun 08, 2022 7:00am EDT

Immunovant Achieves Alignment with FDA on Plans for Phase 3 Clinical Trials of Batoclimab in Thyroid Eye Disease and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022

  • 1
  • 2
  • 3
  • 4
  • 5
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
©2023 Immunovant, Inc. All Rights Reserved.
Privacy Policy Terms of Use Disclaimer Sitemap Manage Cookie Preferences